

Jeroen P Jansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11745234/publications.pdf>

Version: 2024-02-01

67
papers

9,413
citations

172457

29
h-index

110387

64
g-index

69
all docs

69
docs citations

69
times ranked

11557
citing authors

#	ARTICLE	IF	CITATIONS
1	Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. <i>Medical Decision Making</i> , 2022, 42, 906-922.	2.4	2
2	Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. <i>BMC Medicine</i> , 2021, 19, 307.	5.5	7
3	The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1236-1242.	0.9	3
4	Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucl versus Tisagenlecleucl in Relapsed/Refractory Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1581-1588.	2.0	40
5	Multivariate network meta-analysis of survival function parameters. <i>Research Synthesis Methods</i> , 2020, 11, 443-456.	8.7	7
6	Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucl versus Tisagenlecleucl in Relapsed/Refractory Large B Cell Lymphoma". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e335-e336.	2.0	4
7	Heterogeneity and Subgroup Analysis in Network Meta-Analysis. <i>Emerging Topics in Statistics and Biostatistics</i> , 2020, , 369-385.	0.1	2
8	Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 733-751.	1.4	6
9	Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. <i>BMC Medical Research Methodology</i> , 2019, 19, 182.	3.1	22
10	Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework. <i>Value in Health</i> , 2019, 22, S12-S17.	0.3	8
11	R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment. <i>Value in Health</i> , 2019, 22, 575-579.	0.3	31
12	Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact. <i>Statistics in Medicine</i> , 2019, 38, 2505-2523.	1.6	13
13	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2019, 37, 829-843.	3.3	16
14	An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. <i>Journal of Medical Economics</i> , 2018, 21, 340-347.	2.1	24
15	The number needed to treat and relevant between-trial comparisons of competing interventions. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 865-871.	1.9	3
16	Relevance of American Society of Clinical Oncology Value Framework Will Be Improved if It Is Based on Network Meta-Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 1131-1132.	1.6	2
17	Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. <i>Journal of Medical Economics</i> , 2017, 20, 703-714.	2.1	15
18	Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 681-688.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 348.	1.9	0
20	Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. <i>Clinical Therapeutics</i> , 2016, 38, 2628-2641.e5.	2.5	44
21	Incorporating alternative design clinical trials in network meta-analyses. <i>Clinical Epidemiology</i> , 2015, 7, 29.	3.0	6
22	Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 102.	3.0	15
23	Heterogeneity in Meta-analysis of FDG-PET Studies to Diagnose Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 419.	7.4	9
24	Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials. <i>Value in Health</i> , 2015, 18, 234-249.	0.3	24
25	Une méta-analyse en réseau de l'efficacité des analgésiques opioïdes dans la prise en charge des épisodes d'accès douloureux paroxystiques d'origine cancéreuse. <i>Douleurs</i> , 2015, 16, 61-76.	0.0	0
26	The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. <i>Annals of Internal Medicine</i> , 2015, 162, 777-784.	3.9	4,590
27	Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 923.	7.4	541
28	Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs â€” a systematic review and network meta-analysis. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 102.	2.4	59
29	A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. <i>BMC Medicine</i> , 2014, 12, 93.	5.5	69
30	Basedoxifene versus Oral Bisphosphonates for the Prevention of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis at Higher Risk of Fracture: A Network Meta-Analysis. <i>Value in Health</i> , 2014, 17, 424-432.	0.3	27
31	A Network Meta-Analysis of the Efficacy of Opioid Analgesics for the Management of Breakthrough Cancer Pain Episodes. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 772-785.e5.	1.2	69
32	Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. <i>Value in Health</i> , 2014, 17, 157-173.	0.3	248
33	Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. <i>BMC Medicine</i> , 2013, 11, 159.	5.5	427
34	Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis. <i>Respiratory Research</i> , 2013, 14, 100.	3.6	60
35	Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. <i>BMC Medical Research Methodology</i> , 2013, 13, 147.	3.1	44
36	Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models. <i>Value in Health</i> , 2013, 16, 403-417.	0.3	29

#	ARTICLE	IF	CITATIONS
37	Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma. <i>Oncologist</i> , 2012, 17, 1376-1385.	3.7	23
38	Treatment of Ureteral and Renal Stones: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. <i>Journal of Urology</i> , 2012, 188, 130-137.	0.4	97
39	Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 798-807.	5.0	50
40	A network meta-analysis of the efficacy of inhaled antibiotics for chronic <i>Pseudomonas</i> infections in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 419-426.	0.7	39
41	Efficacy of Once-Daily Indacaterol Relative to Alternative Bronchodilators in COPD: A Patient-Level Mixed Treatment Comparison. <i>Value in Health</i> , 2012, 15, 524-533.	0.3	14
42	Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. <i>BMC Medical Research Methodology</i> , 2012, 12, 152.	3.1	66
43	Efficacy of once-daily indacaterol 75 µg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis. <i>BMC Pulmonary Medicine</i> , 2012, 12, 29.	2.0	22
44	Efficacy of indacaterol 75 µg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. <i>International Journal of COPD</i> , 2012, 7, 415.	2.3	7
45	Network meta-analysis of individual and aggregate level data. <i>Research Synthesis Methods</i> , 2012, 3, 177-190.	8.7	70
46	An Economic Evaluation of Short-Acting Opioids for Treatment of Breakthrough Pain in Patients with Cancer. <i>Value in Health</i> , 2011, 14, 274-281.	0.3	28
47	Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. <i>Value in Health</i> , 2011, 14, 429-437.	0.3	606
48	Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. <i>Value in Health</i> , 2011, 14, 417-428.	0.3	822
49	Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. <i>Current Medical Research and Opinion</i> , 2011, 27, 225-238.	1.9	17
50	Comparative Effectiveness of Efavirenz, Protease Inhibitors, and Raltegravir-Based Regimens as First-Line Treatment for HIV-Infected Adults: A Mixed Treatment Comparison. <i>HIV Clinical Trials</i> , 2011, 12, 175-189.	2.0	15
51	Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis. <i>International Journal of COPD</i> , 2011, 6, 329.	2.3	21
52	The Efficacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-Analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 275-284.e2.	3.4	87
53	Network meta-analysis of survival data with fractional polynomials. <i>BMC Medical Research Methodology</i> , 2011, 11, 61.	3.1	111
54	Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-14.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 504-514.	1.5	10
56	Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. <i>Annals of Hematology</i> , 2010, 89, 919-926.	1.8	15
57	Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 425-441.	3.4	90
58	Network meta-analysis of parametric survival curves. <i>Research Synthesis Methods</i> , 2010, 1, 258-271.	8.7	81
59	The Critical Role Of Observational Evidence In Comparative Effectiveness Research. <i>Health Affairs</i> , 2010, 29, 1826-1833.	5.2	63
60	Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis. <i>Pharmacoeconomics</i> , 2010, 28, 323-344.	3.3	12
61	Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. <i>Current Medical Research and Opinion</i> , 2009, 25, 1861-1868.	1.9	44
62	Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy. <i>Value in Health</i> , 2008, 11, 830-841.	0.3	21
63	Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment Comparisons. <i>Value in Health</i> , 2008, 11, 956-964.	0.3	283
64	Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. <i>European Journal of Haematology</i> , 2008, 81, 467-474.	2.2	48
65	A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. <i>European Journal of Haematology</i> , 2007, 78, 532-539.	2.2	63
66	Self-monitoring of glucose in type 2 diabetes mellitus:a Bayesian meta-analysis of direct and indirect comparisons. <i>Current Medical Research and Opinion</i> , 2006, 22, 671-681.	1.9	111
67	Lumbar Posture during Work among Nurses and Office Workers and the Relation to Back Problems: Statistical Analysis of Angle-vs-Time Data. <i>Proceedings of the Human Factors and Ergonomics Society</i> , 2000, 44, 5-465-5-468.	0.3	0